New combo therapy shows promise for Hard-to-Treat gut cancer
NCT ID NCT04258956
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a combination of two drugs—avelumab (an immunotherapy) and axitinib (a targeted therapy)—in 58 adults with advanced gastrointestinal stromal tumor (GIST) that had worsened after standard treatments. The main goal was to see how many patients were still cancer-free at 3 months. The trial is now complete, and results will help determine if this combination is worth further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- avelumab (immunotherapy) and axitinib (targeted therapy)
- What this could lead to
- If successful, this combination could offer a new treatment option for advanced GIST patients who have run out of standard therapies.
- What could go wrong
- This is a small, single-arm Phase 2 trial with no comparison group, so results may not be definitive. The combination may cause side effects like fatigue, high blood pressure, or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Maria Sklodowska-Curie National Research Institue of Oncology
Warsaw, 02-781, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Brain-Cancer drug take on a stubborn stomach tumor?
- Study aims to pinpoint ideal imatinib dose for GIST patients
- New hope for stubborn GIST: experimental drug DCC-2618 enters safety testing
- New drug cocktail targets tough stomach cancer in Last-Resort patients
- New hope for rare stomach cancer: chemo drug shows promise in early trial
- New oral paclitaxel trial offers hope for Hard-to-Treat GIST